Awareness, knowledge, and attitudes related to HIV pre-exposure prophylaxis and other prevention strategies among physicians from Brazil and Mexico: cross-sectional web-based survey

Hamid Vega-Ramirez1*,†, Thiago S. Torres2†, Centli Guillen-Diaz1, Cristina Pimenta3, Dulce Diaz-Sosa1, Kelika A. Konda4, Alessandro Ricardo Caruso da Cunha3, Rebeca Robles-Garcia1, Marcos Benedetti2, Brenda Hoagland2, Daniel R. B. Bezerra2, Carlos F. Caceres4, Beatriz Grinsztejn5, Valdilea G. Veloso5 and for the ImPrEP Study Group

Abstract

Background: In order to end the HIV epidemic by 2030, combination HIV prevention including pre-exposure prophylaxis (PrEP) should be widely available, especially for the most vulnerable populations. In Latin America and the Caribbean (LAC), only 14 out of 46 countries have access to PrEP. In Brazil and Mexico, PrEP has been provided at no cost through the Public Health System since 2017 and 2021, respectively. Thus, HIV physicians’ perspectives about PrEP and other prevention strategies may differ. This study aimed to compare awareness, knowledge, and attitudes related to PrEP and other prevention strategies among HIV physicians from Brazil and Mexico.

Methods: Cross-sectional, web-based survey targeting physicians who prescribe antiretrovirals from both countries. Participants answered questions on socio-demographic, medical experience, awareness, knowledge, and attitudes towards PrEP and other HIV prevention strategies. We stratified all variables per country and compared frequencies using Chi-square, Fisher exact, and Wilcoxon-Mann-Whitney tests, as appropriate.

Results: From January–October 2020, 481 HIV physicians were included: 339(70.5%) from Brazil, 276(57.4%) male, and median age was 43 years (IQR = 36–53). Awareness of PrEP did not differ between Brazil and Mexico (84.6%), while awareness of other prevention strategies, including post-exposure prophylaxis and new PrEP technologies, was higher in Brazil. More Brazilians perceived U=U as completely accurate compared to Mexicans (74.0% vs. 62.0%, P < .001). Willingness to prescribe PrEP was 74.2%, higher among Brazilians (78.2%, P = .01). Overall, participants had concerns about consistent access to PrEP medication and the risk of antiretroviral resistance in case of acute HIV...
Background
The annual number of new HIV diagnoses has not changed since 2010 (100,000 new infections), with 2.1 million people living with HIV in Latin America and the Caribbean (LAC) by the end of 2020 [1]. Gay, bisexual, and transgender women (TW) remain the most affected populations in the region [1]. In order to end the HIV epidemic by 2030, combination HIV prevention should be widely available especially for the most vulnerable populations, with strategies including behavioral, biomedical, and structural approaches based on human rights, and community-based interventions, such as gender-affirming approaches [2, 3]. Pre-exposure prophylaxis (PrEP) is an effective biomedical prevention strategy to prevent new HIV infections [4, 5]. The World Health Organization strongly recommends the incorporation of daily oral PrEP with tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg (TDF/FTC) into combination HIV prevention package since 2016 [6]. Nevertheless, by the end of June 2021 only 14 out of 46 LAC countries had access to PrEP, mostly through private clinics, non-governmental organizations, pilot studies, or implementation/demonstration projects [7].

Brazil and Mexico host half of LAC population and have the largest gross domestic product in the region [8]. Both countries provide combination HIV prevention at no cost through the public health system, including condoms, post-exposure prophylaxis (PEP), test and treat, and antiretroviral (ART) treatment for all people newly diagnosed with HIV [9, 10]. However, there is different PrEP availability in the two countries [7, 9, 10]. Brazil participated in the iPrEX clinical trial (2007–2010) [11] and conducted the PrEP Brasil Demonstration Study to evaluate acceptability, retention, and adherence of PrEP among MSM and TW (2014–2016) [12]. These two experiences paved the way for Brazil to start providing PrEP at no cost through its national public health service (Brazilian Unified Health System – SUS, in Portuguese) since 2017 [13]. By October 2021, 47,821 Brazilians had initiated PrEP and 27,236 were using PrEP [14]. The Implementation PrEP project (ImPrEP) aims to generate evidence on the acceptability, feasibility, and cost-effectiveness of PrEP among MSM and TW in Brazil, Mexico and Peru, including a large PrEP demonstration study conducted from 2018 to 2021 [15]. ImPrEP was the first opportunity for Mexico to provide PrEP in three cities (Mexico City, Guadalajara and Puerto Vallarta), with 2445 participants under follow-up by the end of June 2021 [16]. In 2021, the Mexican National HIV Program (CENSIDA, in Spanish) and the social security health system launched national pilot PrEP programs [17, 18]. PrEP availability and demand creation including awareness and knowledge of users and health care professional are fundamental for PrEP scale-up among populations vulnerable to HIV. Until 2020, only HIV physicians in the public sector could prescribe PrEP in these two countries. The different stages of PrEP availability and implementation in Brazil and Mexico could lead to differences in HIV physicians’ perspectives about PrEP and other prevention strategies.

Awareness and willingness to prescribe PrEP may increase depending on PrEP availability in the health systems [19]. Nevertheless, physicians may have concerns or perceived barriers about prescribing PrEP [20]. Low knowledge about PrEP, lack of time, cost, antiretroviral resistance, the purview paradox (the belief that PrEP prescription is beyond one’s clinical domain), interpersonal stigma, anticipated risk compensation, and PrEP adherence were the main reported concerns of health care physicians in the USA [20–23]. Low willingness to prescribe PrEP has been associated with providers’ racial bias or prejudice about key populations behavior, especially in their PrEP adherence capacity [24, 25]. Studies in LAC reveal variations in awareness and willingness to prescribe PrEP among general practitioners or physicians with a medical specialty. In 2015, in Guatemala, 69% of internal medicine and infectious disease trainees reported awareness of PrEP, and 87% had willingness to prescribe it [26]. In Brazil, a study conducted between

Conclusions: Although awareness of PrEP was similar in Brazil and Mexico, differences in knowledge and attitudes may reflect the availability and stage of PrEP implementation in these countries. Strengthening and increasing information on PrEP technologies and other HIV prevention strategies among HIV physicians could improve their comfort to prescribe these strategies and facilitate their scale-up in LAC.

Keywords: Pre-exposure prophylaxis, Post-exposure prophylaxis, HIV, Physicians, U=U slogan, Treatment as prevention, Brazil, Mexico, Latin America
2016 and 2017 showed that 75% of infectious disease physicians were aware of PrEP, and between 63 and 69% reported willingness to prescribe PrEP for MSM or sex workers with inconsistent condom use [27]. However, such information is not available for Mexico and for Brazil after PrEP implementation in December 2017.

As part of the ImPrEP project, we conducted a web-based survey among HIV physicians from Brazil and Mexico to understand awareness, knowledge, experience, and attitudes related to PrEP and other HIV prevention strategies, as well as to compare both countries considering the differences in PrEP implementation stage.

Methods

Study design
This was a cross-sectional web-based survey targeting HIV physicians who prescribe ARV from Brazil and Mexico. In both countries, most ARV prescriptions, including PrEP, are performed by physicians working in the public health system (either general practitioners or infectious diseases specialists). HIV physicians who signed electronic informed consent were included. We excluded participants who previously participated in the survey. We used Alchemer® (Brazil) and SurveyMonkey® (Mexico) for programming the questionnaire. The survey was designed based on previous studies [21, 23, 26, 27], and consisted of 37 questions in 22 pages. Participants could only answer questions on one page after completing all items on the previous page. The items related to perceived barriers, concerns or attitudes had a 4-point Likert scale to avoid intermediate options and reduce social desirability bias [28]. We piloted the questionnaire to a small sample of physicians with experience in ARV prescription in both countries. The research team discussed the post-pilot suggestions and adjusted items as needed.

In Brazil, the survey was conducted between January 28 and October 20, 2020. The questionnaire link was sent by e-mail using Mailchimp® to all HIV physicians registered at Siclom (Brazilian National System for antiretroviral prescription and dispensation) and at the Federal Medicine Council (CFM). Those who did not initially respond were sent up to two additional emails. In Mexico, we sent weekly e-mails to HIV physicians between March 15 and September 4, 2020. Twenty-seven out of 32 State HIV Representatives from Mexico provided a list containing 267 HIV physician e-mail contacts.

Variables

Socio-demographic and medical experience
We collected the following demographic characteristics: age (stratified in 26 to 34, 35 to 49, >50 years; and provided as median and interquartile range [IQR]), gender (male/female), race/skin color (White, Mixed [Mestizo in Mexico and Pardo in Brazil], Asian, Black and Indigenous), region of residence (Brazil: North, Northeast, Central-west, Southeast, and South; Mexico: Northeast, North Centre, South Centre, South, West, and East) and living in metropolitan area of State capitals (yes/no). Participants were asked about their medical experience: infectious diseases specialist (yes/no), number of years as medical doctor (MD; ≤5, 6–10, 11–15, 16–20, and >20 years), and number of patients living with HIV under follow-up (None, 1–19, 20–49, ≥50).

Awareness of combination HIV prevention strategies including new PrEP technologies, and comfortableness on prevention counseling
We assessed awareness of combination HIV prevention and PrEP with two separate questions: “Have you ever heard of the combination HIV prevention concept (or PrEP)?”, using a 4-Likert scale for response options (Not at all to Very much). For the analysis, we considered participants who responded Much or Very much as aware. We provided a pre-existing list of other prevention strategies (ie, condoms, treatment as prevention, serosorting, etc) including new PrEP technologies, such as event-driven PrEP and cabotegravir injection [29, 30], and asked HIV physicians to choose all strategies they had previously heard about.

Participants were asked if they would feel comfortable performing activities related to HIV and sexual transmitted infections (STI) prevention (ie, discussing sexual behavior, requesting STI exams, etc). We presented possible answers in a 4-Likert scale (Completely comfortable to Completely uncomfortable) and participants were considered comfortable to perform such activities if they answered Completely comfortable or Comfortable. Participants were also asked about their awareness of the different PrEP technologies, such as TDF/FTC daily dose and cabotegravir injection (yes/no) [29, 30].

Knowledge and attitudes regarding PrEP, PEP and U=U slogan
HIV physicians answered whether they had knowledge of PrEP and PEP national guidelines or had ever received any training, prescribed, or referred a client to receive PrEP or PEP (yes/no). We also asked participants their willingness to prescribe PrEP and in which context or setting they had previously prescribed it: private office, demonstration studies, clinical trials and/or SUS (only for Brazilian participants) (all yes/no). For PEP, we asked about reasons for PEP prescription (occupational, sexual violence, and consensual sex; multiple options were available). Perceived accuracy of the undetectable equals untransmittable (U=U) slogan was assessed following
previous studies (completely accurate vs. not) [31, 32]. Participants were also asked if they had ever been trained on the U=U (yes/no).

**Population who would benefit from PrEP, healthcare services that should offer PrEP, and reasons for not offering PrEP**

We asked HIV physicians which populations would benefit from PrEP from a pre-existing list and which healthcare services should offer PrEP (HIV/STI clinics, specialized clinics, family clinics, private clinics/hospitals and primary care); possible answers were *yes/no* and multiple answers were permitted. We also asked about reasons PrEP should not be offered: “Public PrEP will reduce the budget for antiretroviral treatment”; “Behavioral interventions should be prioritized instead of PrEP”; “Low demand of PrEP users to maintain PrEP as public policy”; “I think PrEP should not be provided by public services”. For each of these items, responses were gathered using a 4-Likert scale *(Strongly disagree to Strongly agree)*. *Strongly agree* and *Agree* responses were considered as *yes*.

**Perceived concerns and barriers to prescribing PrEP**

We provided a pre-existing list of concerns about prescribing PrEP (for instance, consistent access to PrEP medication and risky behavior increase) with possible answers in a 4-Likert scale *(Not concerned to Extremely concerned)*; responses *Somewhat/Extremely concerned* were considered as *yes* for analysis. We also provided a pre-existing list of barriers to prescribe PrEP with possible answers in a 4-Likert scale *(Not a barrier to Strong barrier)*; responses *Moderate/Strong barrier* were considered as *yes*.

**Ethics and consent to participate**

This study was approved by the Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz) Institutional Review Board (CAAE: 94050418.4.0000.5262) in Brazil and the Research Ethics Committee of the National Institute of Psychiatry Ramón de la Fuente Muñiz (CEI/C/038/2018) in Mexico. We did not collect participants’ identification or provide any incentives.

**Statistical analysis**

We used only completed surveys for analysis and we described all study variables frequencies in total and for each country (total number of responses and percentages considering sample size). We compared responses between HIV physicians from Brazil and Mexico using Chi-square and Fisher exact test for categorical variables and Wilcoxon-Mann-Whitney for the continuous variable (age), as appropriate. Questions contained response options *I do not want to answer*, and *I do not know*, which were considered as missing data for analysis and not included in the frequency calculation. The items related to perceived barriers, concerns or attitudes scales were presented in absolute numbers and frequencies; scales were not developed to provide scores. Differences between countries were considered using a threshold $P\leq .05$ for statistical significance. All analyses were performed using Stata/IC 15. Datasets generated and analyzed in this study are available (Additional file 1).

**Results**

Of 704 participants who accessed the survey, 674 (95.7%) acknowledged informed consent and 541 (76.8%) completed the survey. Of these, 11.1% (60/541) reported previous participation in the study and were excluded. Our final sample was composed of 481 HIV physicians, 339 (70.5%) from Brazil and 142 (29.5%) from Mexico. Median age was 43 (IQR 36–53) years; most were male (279/481, 57.4%), self-identified as White (303/481, 63.9%), lived in metropolitan areas of state capitals (327/481, 68%), and were infectious disease specialists (333/481, 69.4%). Compared to Mexico, more HIV physicians from Brazil were younger (26–34 years; 22.3% vs. 12%; $P = .01$), White race (81.2% vs 22.3%; $P < .001$), infectious disease specialists (79.1% vs 46.1%; $P < .001$) and more experienced as MD (> 20 years; 44.2% vs 36.6%; $P = .05$). Conversely, Mexican physicians had more patients living with HIV under follow-up (≥50 patients; 91.3% vs 50.9%; $P < .001$) (Table 1). Most of the Brazilian HIV physicians reported living in the Southeast (55.4%), followed by South (19.2%), Northeast (13.9%), Central West (7.4%), and North (4.1%). For Mexico, most were from the South region (43.7%) followed by Northwest (23.2%), East (11.3%), West (9.2%), Northeast (6.3%), North Centre (5%), and South Centre (1.4%).

Overall, awareness of PrEP and other prevention strategies varied from 48.4% to 87.1% for cervical exams and PEP, respectively (Table 2). Awareness of PrEP was 84.6%, with no difference between countries ($P = .25$). Nevertheless, Brazilian HIV physicians were more aware of most prevention strategies including new PrEP technologies than their Mexican counterparts ($P \leq .05$), except for daily oral TDF/FTC or tenofovir alafenamide/ emtricitabine (TAF/FTC) ($P \geq .63$). Most HIV physicians reported being comfortable performing all HIV/STI prevention activities evaluated with no difference between countries ($P \geq .20$), except risk-reduction counseling, which was higher among Mexican compared to Brazilian physicians (99.3% vs 93.5%; $P < .01$).

Most HIV physicians from both countries knew about the national PrEP guidelines, with no differences between countries ($P = .12$) (Table 3). A higher proportion of
Brazilian compared to Mexican physicians were willing to prescribe PrEP (78.2% vs 64.8%; \( P < .01 \)), previously referred a patient to receive PrEP (72% vs 20.6%; \( P < .001 \)) and had previous experience on prescribing PrEP (49.1% vs 33.3%; \( P < .01 \)), while more Mexicans reported prescriptions at private offices (66% vs 45.1%; \( P = .01 \)). Figure 1 provides the PrEP cascade experience (from awareness to prescription) differences between HIV physicians from Brazil and Mexico. More Brazilians than Mexicans knew about the national PEP guidelines (95.9% vs 83.1%; \( P < .001 \)), previously referred a client to receive PEP (87.3% vs 44.4%; \( P < .001 \)) and reported previous experience on prescribing PEP (92.6% vs 69.7%; \( P < .001 \)), including all reasons for prescribing PEP. In Brazil, more HIV physicians perceived the U=U slogan completely accurate than in Mexico (74.0% vs 62%; \( P < .001 \)), while more Mexicans had been previously trained in U=U (62% vs 38.6%; \( P < .001 \)).

HIV physicians from both countries reported that MSM, sex workers, transgender people, and partners in sero-discordant relationships would be the populations benefiting the most by PrEP (Table 4). Conversely, more
Brazilians than Mexicans agreed that PrEP would benefit almost all populations evaluated (for all, $P \leq 0.001$) except for young adults or adolescents and MSM ($P = 0.46$). More Brazilians than Mexicans reported that PrEP should be offered in specialized clinics (79.9% vs 49.3%; $P < 0.001$) and private clinics/hospitals (40.4% vs 28.9%; $P = 0.02$), while more Mexicans reported it should be offered on HIV/STI clinics (88% vs 79.7%; $P = 0.03$). More Mexicans than Brazilians agreed with all reasons evaluated for not offering PrEP (for all, $P \leq 0.01$); the reason most frequently

---

**Table 2** Awareness of PrEP and other prevention strategies, and comfort with HIV/STI procedures among HIV physicians from Brazil and Mexico, 2020

| Awareness of PrEP and other prevention strategies (yes) | Total $(N = 481)$ | Brazil $(N = 339; 70.5\%)$ | Mexico $(N = 142; 29.5\%)$ | $P$ value$^a$ |
|--------------------------------------------------------|------------------|-----------------------------|-----------------------------|----------------|
| PEP                                                   | 419 (87.1)       | 302 (89.1)                  | 117 (82.4)                  | 0.05           |
| Combination HIV prevention concept                     | 407 (84.6)       | 294 (86.7)                  | 113 (79.6)                  | 0.05           |
| Condoms and lubricants                                | 407 (84.6)       | 303 (89.4)                  | 104 (73.2)                  | <0.001         |
| PrEP                                                   | 407 (84.6)       | 291 (85.8)                  | 116 (81.7)                  | 0.25           |
| Regular HIV/STI testing                               | 393 (81.7)       | 299 (88.2)                  | 94 (66.2)                   | <0.001         |
| Mother to child transmission                          | 371 (77.1)       | 286 (84.4)                  | 85 (59.9)                   | <0.001         |
| Knowledge of partner serology                          | 356 (74)         | 275 (81.1)                  | 81 (57)                     | <0.001         |
| Treatment as prevention                               | 347 (72.1)       | 280 (82.6)                  | 67 (47.2)                   | <0.001         |
| Vaccination for HAV$^b$, HBV$^c$ and HPV$^d$           | 335 (69.7)       | 270 (79.6)                  | 65 (45.8)                   | <0.001         |
| Cervical exams                                         | 233 (48.4)       | 185 (54.6)                  | 48 (33.8)                   | <0.001         |

| Awareness of PrEP Technologies (yes)                   | Total $(N = 481)$ | Brazil $(N = 339; 70.5\%)$ | Mexico $(N = 142; 29.5\%)$ | $P$ value$^a$ |
|--------------------------------------------------------|------------------|-----------------------------|-----------------------------|----------------|
| Daily oral with TDF/FTCe$^e$                            | 444 (92.3)       | 313 (92.3)                  | 131 (92.3)                  | 0.98           |
| Event-Driven PrEP with TDF/FTCe$^e$                    | 262 (54.5)       | 212 (62.5)                  | 50 (35.2)                   | <0.001         |
| Daily oral with TAF/FTCe$^f$                           | 246 (51.1)       | 171 (50.4)                  | 75 (52.8)                   | 0.63           |
| Cabotegravir injection                                 | 202 (42)         | 180 (53.1)                  | 22 (15.5)                   | <0.001         |
| Vaginal ring with antiretroviral                        | 156 (32.4)       | 120 (35.4)                  | 36 (25.4)                   | 0.03           |
| Microbicides                                           | 104 (21.6)       | 82 (24.2)                   | 22 (15.5)                   | 0.03           |
| Implants with antiretroviral                           | 97 (20.2)        | 81 (23.9)                   | 16 (11.3)                   | <0.01          |
| Monoclonal antibodies                                  | 61 (12.7)        | 57 (16.8)                   | 4 (2.8)                     | <0.001         |

| Comfort with HIV/STI prevention procedures (yes)        | Total $(N = 481)$ | Brazil $(N = 339; 70.5\%)$ | Mexico $(N = 142; 29.5\%)$ | $P$ value$^a$ |
|--------------------------------------------------------|------------------|-----------------------------|-----------------------------|----------------|
| Request HIV exam                                       | 477 (99.2)       | 337 (99.4)                  | 140 (98.6)                  | 0.36           |
| Request STI exams                                      | 473 (98.3)       | 335 (98.8)                  | 138 (97.2)                  | 0.20           |
| Evaluation of sexual risk behavior                     | 458 (95.2)       | 324 (95.6)                  | 134 (94.4)                  | 0.57           |
| Risk-reduction counseling                              | 458 (95.2)       | 317 (93.5)                  | 141 (99.3)                  | <0.01          |
| Discuss sexual behavior                                | 454 (94.4)       | 320 (94.4)                  | 134 (94.4)                  | 0.99           |
| Discuss sexual orientation                             | 453 (94.2)       | 317 (93.5)                  | 136 (95.8)                  | 0.33           |
| Provide HIV+ result                                    | 441 (91.7)       | 310 (91.5)                  | 131 (92.3)                  | 0.77           |
| Evaluation of PrEP eligibility                         | 432 (89.8)       | 301 (88.8)                  | 131 (92.3)                  | 0.25           |
| U=U$^g$ counseling                                     | 387 (80.5)       | 274 (80.8)                  | 113 (79.6)                  | 0.75           |
| Request HIV acute infection test$^h$                   | 333 (69.2)       | 333 (98.2)                  | –                           | N/A$^i$        |
| Evaluation of PrEP eligibility$^h$                     | 320 (66.5)       | 320 (94.4)                  | –                           | N/A$^i$        |

$^a$ Chi-square tests for all comparisons, except for Monoclonal antibodies (Fisher’s exact test)

$^b$ HAV Hepatitis A virus

$^c$ HBV Hepatitis B virus

$^d$ HPV Human papilloma virus

$^e$ TDF/FTC Tenofovir disoproxil fumarate / emtricitabine

$^f$ TAF/FTC Tenofovir alafenamide / emtricitabine

$^g$ U=U Undetectable equals untransmittable

$^h$ This question was not available in Mexico

$^i$ N/A Not applicable
reported for not offering PrEP in both countries was the prioritization of behavioral interventions instead of PrEP (54.3%, overall).

Perceived barriers and concerns to prescribe PrEP varied across countries (Table 5). Overall, more Mexican HIV physicians reported concerns and barriers to prescribe PrEP than Brazilians (for all, \( P \leq .05 \)), but more Brazilians reported concerns related to consistent access to PrEP medication (82.9% vs 68.3%; \( P < .001 \)) and barriers related to lack of professionals to prescribe PrEP (62% vs 46.5%; \( P < .01 \)).

Discussion

Our results describe awareness, knowledge, and attitudes related to PrEP and other prevention strategies among HIV physicians from Brazil and Mexico and compare the differences between countries. Although awareness was similar in both countries, willingness to prescribe PrEP was higher in Brazil than Mexico, while barriers and concerns were more frequent in Mexico, which may be explained by the different stages of PrEP implementation in both countries. Awareness and willingness to prescribe PrEP (84.6% & 74.2%) were higher than previous studies conducted in LAC in Guatemala City (69% & 87%) and São Paulo, Brazil (75% & 63–69%) [26, 27], possibly due to increased information about PrEP over time and PrEP implementation in the Brazilian SUS since December 2017 [13]. Our results offer updated information to inform the Ministry of Health, stakeholders, clinicians and policy makers from Brazil, Mexico and other LAC countries on different stages of PrEP implementation [33].

Awareness of all other HIV prevention strategies except daily oral PrEP, including new PrEP technologies, was higher in Brazil than in Mexico [29]. A broader dissemination of information on combination HIV prevention including all available strategies is needed among Mexican HIV physicians to increase their knowledge beyond condoms, PEP, or PrEP. Increasing awareness and knowledge of new PrEP

### Table 3 Knowledge and attitudes regarding PrEP, PEP and U=U among HIV physicians from Brazil and Mexico, 2020

|                      | Total (\(N = 481\)) n (%) | Brazil (\(N = 339; 70.5\%\)) n (%) | Mexico (\(N = 142; 29.5\%\)) n (%) | \(P\) value* |
|----------------------|-----------------------------|-----------------------------------|-----------------------------------|--------------|
| **PrEP (yes)**       |                             |                                   |                                   |              |
| Knowledge of national PrEP guidelines | 387 (81.1) | 281 (82.9) | 106 (76.8) | .12          |
| Willingness to prescribe PrEP | 357 (74.2) | 265 (78.2) | 92 (64.8) | <.01         |
| Ever referred a patient to receive PrEP | 271 (57.7) | 244 (72) | 27 (20.6) | <.001        |
| Ever trained in PrEP | 139 (29) | 93 (27.4) | 46 (32.6) | .25          |
| Ever prescribed PrEP | 209 (44.4) | 162 (49.1) | 47 (33.3) | <.01         |
| **Site of PrEP prescribing** |             |                                   |                                   |              |
| Private office | 104 (49.8) | 73 (45.1) | 31 (66.0) | .01          |
| Demonstration studies | 33 (15.8) | 30 (18.5) | 3 (6.4) | .06          |
| Clinical trials | 18 (8.6) | 16 (9.9) | 2 (4.3) | .38          |
| SUSb | 116 (24.1) | 116 (71.6) | – | N/A4 |
| **PEP (yes)**       |                             |                                   |                                   |              |
| Knowledge of national PEP guidelines | 418 (91.9) | 300 (95.9) | 118 (83.1) | <.001        |
| Ever prescribed PEP | 413 (85.9) | 314 (92.6) | 99 (69.7) | <.01         |
| Ever referred a patient to receive PEP | 359 (76.6) | 296 (87.3) | 63 (44.4) | <.001        |
| Ever trained in PEP | 209 (43.5) | 148 (43.7) | 61 (43) | 89          |
| Reasons for PEP prescription |             |                                   |                                   |              |
| Occupational | 331 (80.1) | 288 (91.7) | 43 (43.4) | <.001        |
| Consensual sex | 278 (67.3) | 252 (80.3) | 26 (26.3) | <.001        |
| Sexual violence | 275 (66.6) | 231 (73.6) | 44 (44.4) | <.001        |
| **U=Uc (yes)**      |                             |                                   |                                   |              |
| Perceived U=U slogan as completely accurate | 339 (70.5) | 251 (74.0) | 88 (62.0) | <.001        |
| Ever trained in U=U | 219 (45.5) | 131 (38.6) | 88 (62.0) | <.001        |

* Chi-square tests for all comparisons, except for Site of PrEP prescribing (Fisher’s exact test)

b SUS: Brazilian Unified Health System (in Portuguese)

c U=U Undetectable equals untransmittable

d N/A Not applicable
Table 4  Populations who would benefit from PrEP, Healthcare Services that should offer PrEP, and Reasons PrEP should not be offered according to HIV physicians from Brazil and Mexico, 2020

| Populations who would benefit from PrEP (yes)                                      | Total (N = 481) | Brazil (N = 339; 70.5%) | Mexico (N = 142; 29.5%) | P value\(^a\) |
|---------------------------------------------------------------------------------|-----------------|-------------------------|-------------------------|---------------|
| Gay, bisexual, and other men who have sex with men (MSM)                        | 426 (88.6)      | 305 (90)                | 121 (85.2)              | .13           |
| Sex workers                                                                    | 422 (87.7)      | 327 (96.5)              | 95 (66.9)               | <.001         |
| Transgender people                                                             | 388 (80.7)      | 286 (84.4)              | 102 (71.8)              | .001          |
| Partners in a sero-discordant relationship                                      | 363 (75.5)      | 271 (79.9)              | 92 (64.8)               | <.001         |
| Injectable drug users                                                           | 291 (60.5)      | 227 (67.0)              | 64 (45.1)               | <.001         |
| Young adults or adolescents                                                    | 228 (47.4)      | 157 (46.3)              | 71 (50)                 | .46           |
| Non-injectable drug users                                                      | 188 (36.1)      | 150 (44.2)              | 38 (26.8)               | <.001         |

| Healthcare services that should offer PrEP (yes)                                |                 |                         |                         |               |
|---------------------------------------------------------------------------------|-----------------|-------------------------|-------------------------|---------------|
| HIV/STI clinics                                                                 | 395 (82.1)      | 270 (79.7)              | 125 (88)                | .03           |
| Specialized clinics                                                             | 341 (70.9)      | 271 (79.9)              | 70 (49.3)               | <.001         |
| Family clinics                                                                  | 191 (39.7)      | 143 (42.2)              | 48 (33.8)               | .09           |
| Private clinics/hospitals                                                       | 178 (37)        | 137 (40.4)              | 41 (28.9)               | .02           |
| Primary care                                                                    | 172 (35.8)      | 124 (36.6)              | 48 (33.8)               | .56           |

| Reasons PrEP should not be offered (yes)                                        |                 |                         |                         |               |
|---------------------------------------------------------------------------------|-----------------|-------------------------|-------------------------|---------------|
| Behavioral interventions should be prioritized instead of PrEP*                 | 261 (54.3)      | 148 (43.7)              | 113 (79.6)              | <.001         |
| Public PrEP will reduce the budget for antiretroviral treatment*                | 202 (42)        | 120 (35.4)              | 82 (57.8)               | <.001         |
| I think PrEP should not be provided by public services*                         | 49 (10.2)       | 26 (7.7)                | 23 (16.2)               | <.01          |
| Low number of PrEP users to maintain PrEP as public policy*                     | 43 (8.9)        | 15 (4.4)                | 28 (19.7)               | <.001         |

\(^a\) Chi-square test
technologies under development or recently approved by regulatory agencies, such as cabotegravir injection [30] among healthcare workers in addition to HIV physicians could impact the acceptability and willingness to prescribe these technologies when they become available. Furthermore, almost all HIV physicians reported feeling very comfortable providing HIV/STI prevention counseling and performing clinical activities required for PrEP screening in clinical facilities [21] reflecting a positive attitude towards PrEP.

Although both countries established PEP policies more than 10 years ago [34], previous experience with this prevention strategy was more frequent among Brazilians. Over three-quarters of Brazilian HIV physicians previously prescribed PEP for all evaluated reasons for PEP use (occupational, consensual sex and sexual violence). Conversely, almost half of Mexicans prescribed PEP for occupational and sexual violence and only 26% for consensual sex. These results are worrisome and may indicate stigma and judgement by HIV physicians concerning sexual behavior. Continuous refreshing training and campaigns among Mexican HIV physicians should focus on recommending that PEP should be offered to all individuals with PEP criteria regardless of the reason of HIV exposure, and address physicians’ beliefs.

The proportion of Mexican HIV physicians trained in U=U was higher compared to Brazilians, although a lower proportion of Mexicans perceived the U=U slogan to be accurate. Still, proportions of HIV physicians perceiving U=U as accurate in both countries were still low considering the available scientific evidence of treatment as prevention [35–37] and efforts to increase U=U slogan more broadly since 2018 [38]. Reasons for health providers including HIV physicians to not fully embrace the U=U concept were persistent lack of trust and confidence, and a tendency to withhold the U=U slogan during counseling or clinical visits [39]. Either disbelief, concerns about risk compensation, or stigma towards stereotyped sexual behavior among people living with HIV usually result in a conservative message regarding U=U [40, 41]. Wider dissemination of the protective and preventive power of the U=U slogan among HIV physicians could improve their confidence in conveying this message to their patients living with HIV and help reduce the HIV-related stigma [31].

Brazilian and Mexican HIV physicians agreed that MSM would benefit from PrEP, possibly related to the high rates of HIV prevalence among this population [42]. However, it is worrisome that a relative low proportion of Mexicans did not consider that PrEP would benefit sex

Table 5 Perceived concerns and barriers to prescribe PrEP among HIV physicians from Brazil and Mexico, 2020

| Concerns (yes) | Total (N = 481) n (%) | Brazil (N = 339; 70.5%) n (%) | Mexico (N = 142; 29.5%) n (%) | P valuea |
|---------------|-----------------------|-------------------------------|-------------------------------|---------|
| Consistent access to PrEP medication | 379 (78.6) | 281 (82.9) | 98 (68.3) | <.001 |
| ARVb resistance in case of acute HIV infection or seroconversion | 362 (75.1) | 243 (71.7) | 119 (83.2) | <.01 |
| Risky behavior increasal | 361 (74.9) | 238 (70.2) | 123 (86) | <.001 |
| Users need to take a drug everyday | 361 (74.9) | 255 (75.2) | 106 (74.1) | <.01 |
| Risk of ARV drug resistance | 326 (67.6) | 215 (63.4) | 111 (77.6) | <.01 |
| Severe adverse effects | 270 (56) | 179 (52.8) | 91 (63.6) | 03 |
| Mild adverse effects | 204 (42.3) | 131 (38.6) | 73 (51.1) | 01 |
| Limited availability of ARV for people living with HIV | 266 (55.2) | 177 (52.2) | 89 (62.2) | .04 |
| PrEP efficacy | 177 (36.7) | 112 (33) | 65 (45.5) | 01 |
| Barriers (yes) | | | | |
| Users have low PrEP knowledge | 298 (62.0) | 198 (58.4) | 100 (70.4) | .01 |
| Users have limited capacity for PrEP adherence | 284 (59) | 188 (55.5) | 96 (67.6) | 01 |
| Lack of professionals to prescribe PrEP | 276 (57.4) | 210 (62.0) | 66 (46.5) | <.01 |
| Limited time to discuss PrEP | 171 (35.6) | 111 (32.7) | 60 (42.3) | 05 |
| I have no knowledge about PrEP | 165 (34.3) | 89 (26.3) | 76 (53.5) | <.001 |
| I do not know where to refer a potential PrEP userc | 81 (16.8) | 81 (23.9) | – | N/Ad |

a Chi-square test
b Antiretroviral
c This question was not asked in Mexico as PrEP is not current public policy
d N/A Not applicable
workers, transgender people, partners in sero-discordant relationships, and substance users, all populations at increased vulnerability for HIV infection in Mexico [43]. This could be a reflection of HIV physicians’ beliefs that these populations would not have the ability to adhere to daily oral PrEP and be retained at the clinic for follow-up visits [21]. For example, HIV physicians may delay ART initiation among substance users with recent HIV diagnosis due to their perception of substance users’ diminished ability to adhere to the treatment [44–46]. The same rational could be used by HIV physicians prescribing PrEP to such populations. However, in a recent study conducted in Brazil, transgender women showed high rates of retention after 1 year of PrEP provision and this was attributed to the gender-affirming setting [3]. Welcoming services to the most vulnerable populations may not only increase their retention but also HIV physicians’ perception on who can benefit from PrEP. Lastly, lower proportion of Brazilians considering that PrEP should be beneficial for any population may be related to high awareness of PrEP recommendations in Brazil, as PrEP is cost-effective only when offered to populations with HIV incidence higher than or equal to 3% [6].

Less than half of all the HIV physicians in both countries indicated that primary care and family clinics should offer PrEP, in contrast to some studies showing that HIV physicians believe that primary or family care physicians should prescribe PrEP because they have more HIV-uninfected patients (purview paradox) [23]. In our sample, the majority felt that specialized or HIV/STI clinics would be the most appropriate setting to offer PrEP, probably due to the belief that the physicians in these clinics have more experience prescribing ARV. It is striking that a large proportion of Mexicans agreed that behavioral interventions should be prioritized instead of PrEP use. Increasing the information on the efficacy of behavioral interventions in reducing HIV risk among vulnerable populations compared to the efficacy of PrEP could address this perception bias [47]. Concerns about budget reductions for ART if PrEP were available has been reported in both high- and low-income settings [20, 26].

Perceived barriers and concerns found in our study were similar to those reported by other studies in countries with PrEP availability [21, 22, 26, 27]. In general, ARV resistance or increased sexual risk behavior are common concerns among physicians who can prescribe PrEP to vulnerable populations [21]. However, barriers and concerns were more frequent among Mexicans in 13 of 15 items evaluated here, especially those related to PrEP medication and its daily use. Only those related to the public health system (consistent provision of PrEP and lack of professionals to prescribe PrEP) were higher among Brazilian HIV physicians, reflecting the concerns of physicians in countries where PrEP is already a public health policy. The recent decision to extend PrEP prescriptions to nurses in Brazil may reduce the concern related to available personnel for prescriptions [48].

Strengths & limitations
As strengths, our study is the first to assess the awareness, knowledge, experience, and attitudes related to PrEP and other prevention strategies among HIV physicians from Brazil and Mexico, after these countries approved PrEP as a public health policy or conducted an implementation project. In addition, our results show that the perceived barriers or concerns to prescribing PrEP among physicians are different according to the stage of implementation, so there is a need to address these differences. Conversely, our study has some limitations. The cross-sectional design cannot identify associations or causality between the perceived barriers or concerns and the willingness to prescribe PrEP. We did not assess physicians’ sexual orientation which might have influenced their willingness to prescribe PrEP for key populations, such as MSM or TW. Also, this was a convenience sample, and our results cannot be generalized to all physicians from both countries, including the self-reported collection of data that could be subject to social desirability bias. We had a loss of 32% of participants who accessed and did not complete the survey, which could represent a lack of interest in PrEP or other prevention HIV strategies.

Conclusions
In countries where the HIV epidemic is concentrated among historically stigmatized populations, such as LAC, combination HIV prevention strategies offer an opportunity to reduce new HIV infections. In addition to promoting PrEP use and other HIV prevention strategies among populations vulnerable to HIV, training, awareness-raising, and promotion of prescribing among physicians should also be strengthened. Depending on the stage of PrEP implementation, physicians may perceive obstacles related to the provision of services or lack of information to prescribe PrEP. These barriers should be addressed by HIV national programs in LAC to increase the number of people using HIV prevention technologies, contributing to the goal of ending the HIV epidemic by 2030.

Abbreviations
ARV: Antiretroviral; CENSIDA (in Spanish): Mexican National HIV Program; ImPrEP: Implementation PrEP project; LAC: Latin America and the Caribbean; MSM: Men who have sex with men; PEP: Post-exposure prophylaxis; PrEP: Pre-exposure prophylaxis; STI: Sexual transmitted infections; SUS (in Portuguese): Brazilian Unified Health System; TAF/TFC: Tenofovir alafenamide and emtricitabine; TDF/TFC: Tenofovir disoproxil fumarate and emtricitabine; TW: Transgender women; U=U: Undetectable equals untransmittable.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12913-022-07900-y.

Additional file 1. Dataset PrEP Survey with Physicians from Brazil and Mexico 2020. This file contains the raw data from a survey performed in 2020 about the awareness, knowledge, and attitudes related to pre-exposure prophylaxis and other prevention strategies among physicians from Brazil and Mexico.

Acknowledgments
We thank the Brazilian Ministry of Health staff Antonio Ramos de Carvalho, and the Mexican National (CENSIDA) & States' HIV Programs, and all physicians who answered the study survey. We also thank Lorena Hernández-Carno for help on data collection, and Alicia Piñeirúa-Menéndez who facilitated the contact with each States' HIV Program coordinators. Special thanks to the UN Population Fund office in Mexico for their support in this project.

Authors' contributions
HV-R and TST did the literature search. HV-R, TST and KAK conceived the questionnaire. HV-R, TST, KAK, DD-S, DRBB and CG-D worked on the advertisement of the questionnaire. HV-R and TST performed data cleaning. HV-R and TST analyzed the data and generated the tables and figures. HV-R, TST and KAK reviewed the statistical analyses. HV-R and TST interpreted the data and drafted the manuscript. KAK, DD-S, CG-D, RR-G, BH, CP, MB, BG, CFC and VGV substantially revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Funding
This project was made possible thanks to Unitaid's funding and support. Unitaid accelerates access to innovative health products and lays the foundations for their scale-up by countries and partners. Unitaid is a hosted partnership of WHO. We would like to thank the support of the MoHs of Brazil and Mexico. Thiago S. Torres acknowledge funding from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ).

Availability of data and materials
All data generated or analyzed during this study are included in this published article and its supplementary information files.

Declarations

Ethics approval and consent to participate
The Institutional Review Board of the Instituto Nacional de Infectología Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz) approved the study for Brazil (CAAE: 94050418.4.0000.5262); and the Research Ethics Committee of the National Institute of Psychiatry Ramón de la Fuente Muñiz approved it for Mexico (CEU/C/038/2018). All methods were performed in accordance with the guidelines and regulations of each country, and all participants accepted the informed consent before starting the survey.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Center for Research in Global Mental Health, National Institute of Psychiatry Ramon de la Fuente Muñiz, Calzada México-Xochimilco 101, Col. San Lorenzo Huipulco, A.C. Tlalpan, 14370 Mexico City, Mexico. 2 Instituto Nacional de Infectología Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro, RJ, Brazil. 3 Ministry of Health, Brasília, DF, Brazil. 4 Center for Interdisciplinary Research in Sexuality, Health, and AIDS, Universidad Peruana Cayetano Heredia, Lima, Peru.

References
1. Joint United Nations Programme on HIV/AIDS. Confronting inequalities: Lessons for pandemic responses from 40 years of AIDS. UNAIDS, 2021. Available from: https://www.unaids.org/sites/default/files/media_asset/2021-global-aids-update_en.pdf. Date Accessed: 20 July 2021.
2. Joint United Nations Programme on HIV/AIDS. UNAIDS Terminology Guidelines. UNAIDS, 2015. Available from: https://www.unaids.org/sites/default/files/media_asset/2015_terminology_guidelines_en.pdf. Date Accessed: 20 July 2021.
3. Jallil EM, Torres TS, Luz PM, Monteiro L, Moreira R, Castro C, et al. Low PrEP adherence despite high retention among transgender women in Brazil: the PrEPardas study. J Int AIDS Soc. 2022; Article in press.
4. Dominguez KL, Smith DK, Vasavi T, Crepaz N, Lang K, Heneine W, et al. Updated guidelines for antiretroviral Postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016. Atlanta; 2016. Available from: https://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf
5. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.
6. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. WHO. 2016. Available from: http://apps.who.int/iris/bitstream/10665/208829/1/9789241549684_eng.pdf?ua=1. Date Accessed: 20 July 2021.
7. Global PrEP Tracker [Internet]. PrEP Watch - An Initiative of AVAC. 2021 [cited 7/20/2021]. Available from: https://www.prepwatch.org/wp-content/uploads/2021/07/PW_GlobalTracker_June-2021.xlsx.
8. Gross Domestic Product. GDP by Country: World Bank; Available from: https://www.worldometers.info/gdp/gdp-by-country/. Date Accessed: 24 Feb 2022.
9. Brazilian Health Ministry. What is Combination HIV Prevention? (O que é prevenção combinada?)? Department of Chronic Diseases and Sexually Transmitted Infections, Available from: http://www.aids.gov.br/pt-br/publico-geral/prevencao-combinada/o-que-e-prevencao-combinada. Date Accessed: 07 Oct 2021.
10. Centro Nacional para la Prevención y el Control del VIH y el Sida. National Guideline for HIV & AIDS Prevention (Guía Nacional para la Prevención del VIH y el sida) 2014. Available from: https://www.gov.br/cms/uploads/attachment/file/451493/GUIA_NACIONAL_2014.pdf. Date Accessed: 20 July 2021.
11. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.
12. Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, et al. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brazil: 48 week results of a demonstration study. Lancet HIV. 2018;5(3):e136–e45.
13. Pan American Health Organization. Brazil initiated the implementation of PrEP to prevent new cases of HIV among key higher-risk population groups. 2018. Available from: https://www3.paho.org/hq/index.php?option=com_content&view=article&id=14039 brazil-initiated-the-implementation-of-prep-to-prevent-new-cases-of-hiv-among-key-higher-risk-population-groups&Itemid=135&lang=en. Date Accessed: 20 July 2021.
14. Brazilian Health Ministry. Monitoring Panel of Pre-Exposure Prophylaxis in Brazil (O painel de monitoramento da Profilaxia Pré-Exposição). Department of Chronic Diseases and Sexually Transmitted Infections; Available from: http://www.aids.gov.br/pt-br/painel-prep. Date Accessed: 07 Oct 2021.
15. Torres TS, Konda KA, Vega-Ramirez EH, Elorreaga OA, Diaz-Sosa D, Hoagland B, et al. Factors associated with willingness to use pre-exposure prophylaxis in Brazil, Mexico, and Peru: web-based survey among men who have sex with men. JMIR Public Health Surveill. 2019;5(2):e13771.
16. Veloso VG, Moreira RI, Konda KA, Hoagland B, Vega-Ramirez H, Leite IC, et al. PrEP long-term engagement among MSM and TGW in Latin
21. Petroll AE, Walsh JL, Owczarzak JL, McAuliffe TL, Bogart LM, Kelly JA. HIV providers’ perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav. 2014;18(9):1712–21.

22. Zhang C, McMahon J, Fiscella K, Przybyla S, Braksmajer A, LeBlanc N, et al. Evidence of potential discriminatory HIV pre-exposure prophylaxis (PrEP) prescribing practices for people who inject drugs among a small percentage of providers in the U.S. J Prim Care Community Health. 2022;13:1256–67.

23. Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. Providers’ perceived barriers as biases to provision of equitable PrEP services. J Acquir Immune Defic Syndr. 2021;88(2):165–72.

24. Hull SJ, Tessema H, Thuku J, Scott RK. Providers PrEP: identifying primary health care providers’ biases as barriers to provision of equitable PrEP services. J Acquir Immune Defic Syndr. 2021;88(2):165–72.

25. Rogder AJ, Cambiano V, Brun T, Vernezza P, Collins S, van Lunzen J, et al. Sexual activity without condoms and risk of HIV transmission in Serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. Jama. 2016,316(2):171–81.

26. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumar-Asamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016,375(9):830–9.

27. Smith DR, Mendoza MC, Stryker JE, Rose CE. PrEP awareness and attitudes in a National Survey of primary care clinicians in the United States, 2009-2015. PLoS One. 2016,11(6):e0156592.

28. Plebanski M, Welsh J, Azzini F, et al. Effect of repeated cycles of pre-exposure prophylaxis (PrEP) on the risk of HIV infection in serodiscordant couples: a randomised control trial. Lancet HIV. 2018,5(8):e383–97.

29. Boffetto M, Winkelmayer WC, Garvey M, et al. A meta-analysis of the effectiveness of public health interventions to reduce HIV/STIs among men who have sex with men: implications for Scale-up in other high burden urban areas. PLoS One. 2017,12(1):e0173057.

30. Ferreira NB, Vasconcelos R, Hojlund JC, Kallas EG, Avelino-Silva VI. Attitudes and knowledge about human immunodeficiency virus pre-exposure prophylaxis among healthcare professionals in the United States: implications from a systematic review and Meta-analysis. AIDS Patient Care STDs. 2019;33(12):507–27.

31. Torres TS, Cox J, Marins LM, Bezerra DR, Veloso VG, Grinsztejn B, et al. A call for more research on sexual behavior and HIV: the impact of serodiscordance on the spread of HIV. AIDS Behav. 2017;21(5):1256–67.

32. Petroll AE, Walsh JL, Owczarzak JL, McAuliffe TL, Bogart LM, Kelly JA. HIV providers’ perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav. 2014;18(9):1712–21.

33. Plebanski M, Welsh J, Azzini F, et al. Effect of repeated cycles of pre-exposure prophylaxis (PrEP) on the risk of HIV infection in serodiscordant couples: a randomised control trial. Lancet HIV. 2018,5(8):e383–97.

34. Brazilian Health Ministry. Clinical Protocol and Therapeutic Guidelines for the Prevention and Treatment of HIV/AIDS. Brasilia: D/F; Department of Chronic Diseases and Sexually Transmitted Infections; 2012. Available from: https://www.gov.br/ansa/portal/pt/assunto/previnacaoha/indicadores/pastas/protocolo-clinico-diagnosis-terapeuticas-para-pratopatologia-peso-exposicao-de-risco-de-infecao-pelo-hiv/. Access date: 7 Oct 2021.

35. Bavintron BR, Pinto AN, Panuphayak N, Grinsztejn B, Prestage GP, Zablotska-Manos IB, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018,5(8):e383–97.

36. Rodgers AJ, Cambiano V, Brun T, Vernezza P, Collins S, van Lunzen J, et al. Sexual activity without condoms and risk of HIV transmission in Serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. Jama. 2016,316(2):171–81.

37. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumar-Asamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016,375(9):830–9.

38. The LH. UseU taking off in 2017. Lancet HIV. 2017;4(11):e475.

39. Calabrese SK, Mayer KH. Providers should discuss UseU with all patients living with HIV. Lancet HIV. 2019;6(4):e211–e3.

40. Ngure K, Ongolly F, Dolla A, Awour M, Mugwanya K, Irungu E, et al. ‘I just believe there is a risk’ understanding of undetectable equals untransmissible (U = U) among health providers and HIV-negative partners in serodiscordant relationships in Kenya. J Int AIDS Soc. 2020,23(3):e25466.

41. Calabrese SK, Mayer KH. Stigma impedes HIV prevention by stifling patient-provider communication about U = U. J Int AIDS Soc. 2020,23(7):e25559.

42. Coelho LE, Torres TS, Veloso VG, Grinsztejn B, Jillil EM, Wilson EC, et al. The prevalence of HIV among men who have sex with men (MSM) and young MSM in Latin America and the Caribbean: a systematic review. AIDS Behav. 2021,25(10):3223–37.

43. Centro Nacional para la Prevención y el Control del VIH y el Sida. Newsletter of Comprehensive Care for People Living with HIV (Boletín de Atención Integral de Personas que Viven con VIH). 2021. Available from: https://www.gob.mx/cms/uploads/attachment/file/684194/BAI_DAL_2021_4.pdf. Date Accessed: 22 Feb 2022.

44. Loughlin A, Metsch L, Gardner L, Anderson-Mahoney P, Barrigan M, Strathdee S. Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users. AIDS. 2004,16(4):485–500.

45. Tomori C, Go VF, Tuan LE N, Huang NM, Binh NT, Zelaya CE, et al. ‘In their perception we are addicts’: social vulnerabilities and sources of support for men released from drug treatment centers in Vietnam. Int J Drug Policy. 2014;25(5):897–904.

46. Garcia de la Hera M, Davo MC, Ballester-Anon R, Vioque J. The opinions of health care professionals in the United States on Antiretroviral treatment and health services in Valencia, Spain. Evalu Health Prof. 2011,34(3):349–61.

47. Covey J, Rosenthal-Stott HE, Howell SJ. A synthesis of meta-analytic evidence of behavioral interventions to reduce HIV/STIs. J Behav Med. 2016,39(3):371–85.

48. Garcia de la Hera M, Davo MC, Ballester-Anon R, Vioque J. The opinions of health care professionals in the United States on Antiretroviral treatment and health services in Valencia, Spain. Evalu Health Prof. 2011,34(3):349–61.

49. Covas FJ, Dori M, Ciriaco AC, van Lunzen J, Sciama R, Panaquilla KC, et al. A call to action for research data, including large and complex data types. Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress. Learn more: biomedcentral.com/submissions